Biogen signs ‘$1bn’ deal to make eye treatments

07-07-2015

Biogen signs ‘$1bn’ deal to make eye treatments

Serg Zastavkin / Shutterstock.com

Biotechnology company Biogen has agreed a partnership potentially worth $1 billion with gene therapy business AGTC to develop eye treatments.


Biogen, AGTC, eye-treatment, licensing agreement, biotechnology

LSIPR